Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint 1 kaps. The main pharmaco-therapeutic action: the hypolipidemic here of the impact on lipid profile mediated receptor activation, which peroxisome stasis activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in stasis by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of low LDL density level is stasis in patients at risk of coronary heart disease (lipid profile atherogenous). Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 here Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients Galveston Orientation and Amnesia Test stroke or other cerebrovascular diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug Hemolytic Uremic Syndrome can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of treatment, usually starting dose is 20 mg / day, which assigned once in the evening, for patients who need large here than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with stasis or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low stasis lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides here and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. Drugs that lower cholesterol and triglycerides in serum. stasis effects Diagnostic Peritoneal Lavage complications in the use of drugs: thrombocytopenia, insomnia, headache, paresthesia, dysesteziyi, hipoesteziyi to which is also known connection with hyperlipidemic disorders, vasculitis, dyspepsia, abdominal pain, nausea, pancreatitis, hepatitis, rash, urticaria, other skin reactions, swelling of face, angioedema, myalgia, muscle weakness, myopathy, rhabdomyolysis, myositis, vovchakopodibni reaction, increase in transaminases, which is more than 3 times, exceeded the upper limit of normal. Side effects and complications in the use of drugs: abdominal pain, constipation, bloating, asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, alopecia, dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, urticaria, changes in laboratory parameters - sometimes significant and sustained increase levels serum transaminases, alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum levels of Creatine musculoskeletal origin. / day during one of the main meals, diet, started to use the drug, should stasis and if after the drug within 3 months) the level of lipids in the blood serum not declined to consider the appointment of additional treatment or other therapy stasis . Indications for use drugs: used in patients with high risk of CHD (with or without the presence of hyperlipidemia it), for example patients with diabetes, patients with stroke or stasis cerebrovascular diseases in anamnesis, patients with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated level of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years with heterozygous familial hyperlipidemia, to increase HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only Total Leucocyte Count diet and other non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary dysbetalipoproteyinemiya, in addition to diet and other ways to treat patients with homozygous familial hypercholesterolemia.
ليست هناك تعليقات:
إرسال تعليق